Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Holding BLUE?
Track your performance easily
BLUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $5.53
Previous Close$0.47
Volume1.43M
Average Volume (3M)7.37M
Market Cap
$92.11M
Enterprise Value$336.72M
Total Cash (Recent Filing)$144.07M
Total Debt (Recent Filing)$390.42M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Nov 05, 2024EPS Estimate
-$0.36Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding193,913,585
10 Day Avg. Volume3,575,625
30 Day Avg. Volume7,374,133
Standard Deviation0.22
R-Squared0.04
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)1.73
Price to Sales (P/S)1.65
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.13
Enterprise Value/Gross Profit-83.55
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$3.57Price Target Upside651.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bluebird Bio News
PremiumCompany Announcements
Bluebird Bio Announces Restructuring and Targets Break-Even
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEarly indicators point to demand for bluebird's therapies being more robust than is appreciated by the current valuation.
Market DemandEncouraged to hear that 40+ patients are currently scheduled for cell collections by year-end, which should yield a substantial uptick in revenues.
Operational EfficiencyRestructuring provides a cash-efficient path to break-even, with cost reduction efforts expected to reduce operating expenses by 20% by 3Q25 and allow for break-even to be achieved by 2H25.
Bears Say
Earnings OutlookAnalyst decreases the FY24-‘25 sales forecasts and notably lowers the Lyfgenia peak sales to $730m from prior $970m.
Financial HealthManagement amends Hercules agreement, pushing milestones into the next year and adding requirement of near-term financing, which could result in near-term dilution.
Financial PerformanceThe company's $16.1M in 2Q revenues were below Street expectations of $24M.
---
Ownership Overview
0.44% Insiders
14.04% Mutual Funds
0.10% Other Institutional Investors
75.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $0.45 and its highest was $5.53 in the past 12 months.
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Nov 05, 2024 which is tomorrow.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on Aug 14, 2024. The company reported -$0.407 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.01.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.36.
How many shares outstanding does bluebird bio have?
bluebird bio has 193,913,590 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.407 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went down -23.585%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Woodline Partners LP. It holds bluebird bio’s shares valued at 954K.
---
Bluebird Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.57 (651.58% Upside)
$3.57 (651.58% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 9.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.14%
12-Months-Change
Fundamentals
Return on Equity
-177.63%
Trailing 12-Months
Asset Growth
-17.82%
Trailing 12-Months
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q2 2024
0:00 / 0:00
---
BLUE Stock 12 Month Forecast
Average Price Target
$3.57
▲(651.58% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+13.55%
reiterated a sell rating 6 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +13.55% per trade.
---